KEAP1 inhibitors and uses thereof

KEAP1 inhibitors and Nrf2 activators, represented by compounds of formula (I), (II), (III), and (IV), address the need for improved treatments of immunological disorders by enhancing cellular antioxidant capacity and reducing oxidative stress through Nrf2 modulation.

WO2026128791A1 Publication Date: 2026-06-18VIVIDION THERAPEUTICS INC
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
VIVIDION THERAPEUTICS INC
Filing Date
2025-12-12
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Immunological disorders such as inflammatory bowel disease and ulcerative colitis lack effective therapeutic options, and existing treatments do not adequately address oxidative stress and inflammation.

⚗Method used

Development of KEAP1 inhibitors and activators of Nrf2, such as compounds of formula (I), (II), (III), and (IV), which modulate KEAP1 to indirectly activate Nrf2, thereby increasing antioxidant capacity and reducing oxidative stress in cells.

🎯Benefits of technology

The compounds enhance cellular protection against oxidative stress, providing therapeutic benefits for immunological disorders by increasing Nrf2 activity and reducing oxidative damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

Compounds and methods for activating Nrf2 by inhibiting KEAP1.
Need to check novelty before this filing date? Find Prior Art